US20030119734A1 - Stable formulation of modified GLP-1 - Google Patents

Stable formulation of modified GLP-1 Download PDF

Info

Publication number
US20030119734A1
US20030119734A1 US10/185,923 US18592302A US2003119734A1 US 20030119734 A1 US20030119734 A1 US 20030119734A1 US 18592302 A US18592302 A US 18592302A US 2003119734 A1 US2003119734 A1 US 2003119734A1
Authority
US
United States
Prior art keywords
mg
ml
glp
compound
ph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/185,923
Inventor
James Flink
Silke Larsen
Simon Jensen
Dorthe Engelund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to DKPA200101011 priority Critical
Priority to DKPA200101010 priority
Priority to DKPA200101010 priority
Priority to DKPA200101011 priority
Priority to DKPA200101052 priority
Priority to DKPA200101053 priority
Priority to DKPA200101052 priority
Priority to DKPA200101053 priority
Priority to US30829701P priority
Priority to US30832501P priority
Priority to DKPA200200092 priority
Priority to DKPA200200093 priority
Priority to DKPA200200092 priority
Priority to DKPA200200093 priority
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US10/185,923 priority patent/US20030119734A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JENSEN, SIMON BJERREGAARD, LARSEN, SILKE MOLLER, ENGELUND, DORTHE KOT, FLINK, JAMES M.
Publication of US20030119734A1 publication Critical patent/US20030119734A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27545250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030119734(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons

Abstract

Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.

Description

    FIELD OF THE INVENTION
  • The present invention relates to pharmaceutical formulations comprising GLP-1 compounds, uses thereof and methods for preparing said formulations. [0001]
  • BACKGROUND OF THE INVENTION
  • Peptides are widely used in medical practice, and since they can be produced by re-combinant DNA technology it can be expected that their importance will increase also in the years to come. [0002]
  • The hormones regulating insulin secretion belong to the so-called enteroinsular axis, designating a group of hormones, released from the gastrointestinal mucosa in response to the presence and absorption of nutrients in the gut, which promote an early and potentiated release of insulin. The enhancing effect on insulin secretion, the so-called incretin effect, is probably essential for a normal glucose tolerance. Many of the gastrointestinal hormones, including gastrin and secretin (cholecystokinin is not insulinotropic in man), are insulinotropic, but the only physiologically important ones, those that are responsible for the incretin effect, are the glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1(GLP-1). Because of its insulinotropic effect, GIP, isolated in 1973 immediately attracted considerable interest among diabetologists. However, numerous investigations carried out during the following years clearly indicated that a defective secretion of GIP was not involved in the pathogenesis of insulin dependent diabetes mellitus (IDDM) or non insulin-dependent diabetes mellitus (NIDDM). Furthermore, as an insulinotropic hormone, GIP was found to be almost ineffective in NIDDM. The other incretin hormone, GLP-1 is the most potent insulinotropic substance known. Unlike GIP, it is surprisingly effective in stimulating insulin secretion in NIDDM patients. In addition, and in contrast to the other insulinotropic hormones (perhaps with the exception of secretin) it also potently inhibits glucagon secretion. Because of these actions it has pronounced blood glucose lowering effects particularly in patients with NIDDM. [0003]
  • GLP-1, a product of the proglucagon, is one of the youngest members of the secretin-VIP family of peptides, but is already established as an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. The glucagon gene is processed differently in the pancreas and in the intestine. In the pancreas, the processing leads to the formation and parallel secretion of 1) glucagon itself, occupying positions 33-61 of proglucagon (PG); 2) an N-terminal peptide of 30 amino acids (PG (1-30)) often called glicentin-related pancreatic peptide, GRPP; 3) a hexapeptide corresponding to PG (64-69); 4) and, finally, the so-called major proglucagon fragment (PG (72-158)), in which the two glucagon-like sequences are buried. Glucagon seems to be the only biologically active product. In contrast, in the intestinal mucosa, it is glucagon that is buried in a larger molecule, while the two glucagon-like peptides are formed separately. [0004]
  • While much attention has been focused on the pharmacological properties of acylated GLP-1 compounds, hitherto little is known about their physico-chemical and solution structural properties. Such knowledge is a prerequisite for rational handling during e.g. production, purification and formulation work and is eventually important for understanding of the structural basis for the protraction mechanism. [0005]
  • It is an important technical challenge to ensure prolonged stability during storage (shelf life) of many protein based drug products due to the inherent lability of macromolecules. Hence, proteins are sensitive to both chemical and physical degradation unlike many small molecules. Chemical degradation involves covalent bonds, such as hydrolysis, racemization, oxidation or crosslinking. Physical degradation involves conformational changes relative to the native structure, which includes loss of higher order structure, aggregation, precipitation or adsorption to surfaces. GLP-1 is known to be prone to instability due to aggregation. Both degradation pathways may ultimately lead to loss of biological activity of the protein drug. [0006]
  • GLP-1 and analogues of GLP-1 and fragments thereof are potentially useful i.a. in the treatment of type 1 and type 2 diabetes. However, solubility limitations and the low stability against the actions of endogenous diaminopeptidyl peptidase limits the usefulness of these compounds, and thus there still is a need for improvements in this field. [0007]
  • In WO 99/43341 are disclosed certain pharmaceutical formulations comprising GLP-1 having a lipophilic substituent. All of the disclosed formulations are maintained at pH 7.4. [0008]
  • In WO 00/37098 are disclosed shelf-stable formulations comprising GLP-1, a preservative, and a tonicity modifier, at pH 8.2 to 8.8. [0009]
  • Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. Processing of preproglucagon to give GLP-1(7-36)amide, GLP-1(7-37) and GLP-2 occurs mainly in the L-cells. A simple system is used to describe fragments and analogues of this peptide. Thus, for example, Val[0010] 8-GLP-1(7-37) (or Val8GLP-1(7-37)) designates a fragment of GLP-1 formally derived from GLP-1 by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally occurring amino acid residue in position 8 (Ala) by Val. Similarly, Lys34(Nε-tetradecanoyl)-GLP-1(7-37) designates GLP-1(7-37) wherein the ε-amino group of the Lys residue in position 34 has been tetradecanoylated. For convenience the amino acid sequence of GLP-1(7-37) is given below, wherein the N-terminal His is no. 7 and the C-terminal Gly is no. 37:
  • His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly. [0011]
  • Where reference in this text is made to C-terminally extended GLP-1 analogues, the amino acid residue in position 38 is Arg unless otherwise indicated, the optional amino acid residue in position 39 is also Arg unless otherwise indicated and the optional amino acid residue in position 40 is Asp unless otherwise indicated. Also, if a C-terminally extended analogue extends to position 41, 42, 43, 44 or 45, the amino acid sequence of this extension is as in the corresponding sequence in human preproglucagon unless otherwise indicated. [0012]
  • SUMMARY OF THE INVENTION
  • We have discovered that certain modified GLP-1 or analogues thereof when formulated in aqueous solution together with a buffer, are physically stable at high concentrations of the modified GLP-1 or analogues thereof, when kept in the pH range from about 7 to about 10. The present formulations are physically stable within a given shelf life period at the recommended storage temperature (typically 2-3 years at 2-8° C.). Furthermore, the present formulations are physically stable during in-use (typically 1 month at accelerated temperatures e.g. 25° C. or 37° C.). The formulations of the invention are also chemically stable thus rendering them shelf-stable and suitable for invasive (eg. injection, subcutaneous injection, intramuscular, intraveneous or infusion ) as well as non-invasive (eg nasal or pulmonary, transdermal or transmucosal e.g. buccal ) means of administration. When the inventive formulation comprising a GLP-1 compound was compared to the same formulation comprising GLP-1(7-37) substituted for the GLP-1 compound, the physical stability was increased considerably, and typically the shelf-life was increased from a few seconds to several months in the tests used. [0013]
  • One object of the present invention is to provide a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; [0014]
  • Another object of the present invention is to provide a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0015]
  • In one aspect of the invention the formulation contains a GLP-1 compound in a concentration from 1 mg/ml to 100 mg/ml. [0016]
  • In another aspect of the invention the formulation has a pH from 7.5 to 10. [0017]
  • In one embodiment the GLP-1 compound is Arg[0018] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).
  • DESCRIPTION OF THE INVENTION
  • In one aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; [0019]
  • provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0020]
  • In another aspect the invention relates to a pharmaceutical formulation comprising a GLP-1compound, and a buffer, wherein said GLP-1 compound is GLP-1 (7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; [0021]
  • provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0022]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0023]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0024]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0025]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0026]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising prepararing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0027]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising prepararing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0028]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising prepararing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0029]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0030]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0031]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0032]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0033]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0to 10. [0034]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10. [0035]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10. [0036]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10. [0037]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10. [0038]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0039]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0040]
  • In one embodiment of the invention the pharmaceutical formulation is an aqueous formulation, i.e. a formulation comprising water. Such formulation is typically a solution or a suspension. In a further embodiment of the invention the pharmaceutical formulation is an aqueous solution. The term “aqueous formulation” is defined as a formulation comprising at least 50% w/w water. Likewise, the term “aqueous solution” is defined as a solution comprising at least 50% w/w water, and the term “aqueous suspension” is defined as a suspension comprising at least 50% w/w water. [0041]
  • In another embodiment the pharmaceutical formulation is a freeze-dried formulation, whereto the physician or the patient adds the solvent prior to use. [0042]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0043]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0044]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0045]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0046]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0047]
  • In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0048]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0049]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10. [0050]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0051]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0052]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0053]
  • In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent. [0054]
  • In a further aspect the present invention relates to a method of reducing blood glucose levels, treating diabetes type I, diabetes type II, obesity, or inhibiting gastric acid secretion, inhibiting apoptosis of β-cells, or stimulating the proliferation of β-cells, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0055]
  • In a further aspect the present invention relates to a method of reducing blood glucose levels, treating diabetes type I, diabetes type II, obesity, or inhibiting gastric acid secretion, inhibiting apoptosis of β-cells, or stimulating the proliferation of β-cells comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0056]
  • In a further aspect the present invention relates to a method of treating gastric ulcers comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0057]
  • In a further aspect the present invention relates to a method of treating gastric ulcers comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0058]
  • In a further aspect the present invention relates to a method of treating myocardial infarct comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0059]
  • In a further aspect the present invention relates to a method of treating myocardial infarct comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0060]
  • In a further aspect the present invention relates to a method of treating impaired glucose tolerance (IGT) comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0061]
  • In a further aspect the present invention relates to a method of treating impaired glucose tolerance (IGT) comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0062]
  • In a further aspect the present invention relates to a method of reducing body weight in a subject in need of body weight reduction comprising administering to the subject an effective amount sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks, of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0063]
  • In a further aspect the present invention relates to a method of reducing body weight in a subject in need of body weight reduction comprising administering to the subject an effective amount sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks, of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0064]
  • In a further aspect the present invention relates to a method of treating dyslipidemia, stroke, left ventricular hypertrophy, arrhythmia, bacteraemia, septicaemia, irritable bowel disease, functional dyspepsia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0065]
  • In a further aspect the present invention relates to a method of treating dyslipidemia, stroke, left ventricular hypertrophy, arrhythmia, bacteraemia, septicaemia, irritable bowel disease, functional dyspepsia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10. [0066]
  • The term “an effective amount” is the effective dose to be determined by a qualified practitioner, who may titrate dosages to achieve the desired response. Factors for consideration of dose will include potency, bioavailability, desired pharmacokinetic/pharmacodynamic profiles, condition of treatment (e.g. diabetes, obesity, weight loss, gastric ulcers), patient-related factors (e.g. weight, health, age, etc.), presence of co-administered medications (e.g. insulin), time of administration, or other factors known to a medical practitioner. [0067]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing blood glucose levels. [0068]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing blood glucose levels. [0069]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type I. [0070]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type I. [0071]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type II. [0072]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type II. [0073]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1 (7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating obesity. [0074]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating obesity. [0075]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing body weight, typically for reducing body weight in a type 2 diabetic subject. [0076]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing body weight, typically for reducing body weight in a type 2 diabetic subject. [0077]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating gastric ulcers. [0078]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating gastric ulcers. [0079]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for inhibition of apoptosis of β-cells. [0080]
  • In a further aspect the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for inhibition of apoptosis of β-cells. [0081]
  • The term “treatment” is defined as the management and care of a patient, e.g. a mammal, in particular a human, for the purpose of combating the disease, condition, or disorder and includes the administration of a GLP-1 compound to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. Pharmaceutical compositions containing a GLP-1 compound according to the present invention may be administered parenterally to patients in need of such a treatment. Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a solution or suspension for the administration of the GLP-1 compound in the form of a nasal or pulmonal spray. As a still further option, the pharmaceutical compositions containing the GLP-1 compound of the invention can also be adapted to transdermal administration, e.g. from a patch, optionally a iontophoretic patch, or transmucosal, e.g. bucal, administration. [0082]
  • A pharmaceutical formulation is found to be physically unstable when it exhibits turbidity. A pharmaceutical formulation of GLP1(7-37) is found to be physically unstable as it turns out to be turbid momentaneously after preparation, whereas the same pharmaceutical formulation comprising a GLP-1 compound, for example Arg[0083] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), is found to be physically stable for more than 90 days at 5° C. Some of the present formulations are physically stable for more than 11 months and for more than 22 months at 5° C.
  • Physical stability of the formulations is evaluated by means of visual inspection and turbidity after storage of the formulation at different temperatures in top filled glass cartridges for various time periods. Visual inspection of the formulations is performed in a sharp focused light with a dark background. The turbidity of the formulation is characterized by a visual score ranking the degree of turbidity from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3). A formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight. [0084]
  • In one embodiment of the invention the pharmaceutical formulation comprising the GLP-1 compound is physically stable for more than 12 weeks and for more than 15 months at 5° C. as measured by visual inspection. [0085]
  • In another embodiment of the invention the pharmaceutical formulation comprising the GLP-1 compound is physically stable for more than 12 weeks at 25° C. as measured by visual inspection. [0086]
  • In a further embodiment of the invention the pharmaceutical formulation comprising the GLP-1 compound is physically stable for more than 12 weeks at 37° C. as measured by visual inspection. [0087]
  • In another embodiment of the invention the formulation has a pH in the range from 7.5 to 10. In another embodiment of the invention the formulation has a pH in the range from 7.5 to 9.5. In a further embodiment of the invention the formulation has a pH in the range from 7.0 to 9.5. In a further embodiment of the invention the formulation has a pH in the range from 7.0 to 8.0. In a further embodiment of the invention the formulation has a pH in the range from 7.5 to 8.0. In a further embodiment of the invention the formulation has a pH in the range from 9.0 to 10. [0088]
  • In a further embodiment of the invention the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginin, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention. In a preferred embodiment of the invention the buffer is glycylglycine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate or mixtures thereof. [0089]
  • In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 80 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 80 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 50 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 20 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 10 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 10 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1-5 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1-5 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1-0.5 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.6-1 mg/ml. Each one of these specific concentration ranges constitutes an alternative embodiment of the invention. [0090]
  • In a further embodiment of the invention the formulation further comprises a pharmaceutically acceptable preservative. In a further embodiment of the invention the preservative is selected from the group consisting of phenol, m-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, or mixtures thereof. Each one of these specific preservatives constitutes an alternative embodiment of the invention. In a preferred embodiment of the invention the preservative is phenol or m-cresol. [0091]
  • In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific concentration ranges constitutes an alternative embodiment of the invention. [0092]
  • The use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: [0093] The Science and Practice of Pharmacy, 19th edition, 1995.
  • In a further embodiment of the invention the formulation further comprises an isotonic agent. In a further embodiment of the invention the isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a polyhydric alcohol (e.g. propyleneglycol, xylitol, mannitol, sorbitol or glycerol), a monosaccharide (e.g. glucose or maltose), a disccharide (e.g. sucrose), an amino acid (e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), polyethyleneglycol (e.g. PEG400), or mixtures thereof. In a further embodiment of the invention the isotonic agent is selected from the group consisting of sodium chloride, glycerol, mannitol, glucose, sucrose, L-glycine, L-histidine, arginine, lysine or mixtures thereof. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention. In a preferred embodiments of the invention the isotonic agent is mannitol or glycerol. [0094]
  • In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 16 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 17 mg/ml to 50 mg/ml. Each one of these specific concentration ranges constitutes an alternative embodiment of the invention. [0095]
  • The use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: [0096] The Science and Practice of Pharmacy, 19th edition, 1995.
  • In a further embodiment of the invention the formulation further comprises a chelating agent. In a further embodiment of the invention the chelating agent is selected from salts of ethlenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof. Each one of these specific chelating agents constitutes an alternative embodiment of the invention. [0097]
  • In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 2 mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 2 mg/ml to 5 mg/ml. [0098]
  • The use of a chelating agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: [0099] The Science and Practice of Pharmacy, 19th edition, 1995.
  • In a further embodiment of the invention the formulation further comprises a stabiliser selected from the group of high molecular weight polymers or low molecular compounds. In a further embodiment of the invention the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinylalcohol (PVA), polyvinylpyrrolidone, carboxymethylcellulose, different salts (e.g. sodium chloride), L-glycine, L-histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof. Each one of these specific stabilizers constitutes an alternative embodiment of the invention. In a preferred embodiment of the invention the stabiliser is selected from the group consisting of L-histidine, imidazole and arginine. [0100]
  • In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 0.1 mg/ml to 50 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 10 mg/ml to 20 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 20 mg/ml to 30 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 30 mg/ml to 50 mg/ml. [0101]
  • In a further embodiment of the invention the low molecular weight compound is present in a concentration from 0.1 mg/ml to 50 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 10 mg/ml to 20 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 20 mg/ml to 30 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 30 mg/ml to 50 mg/ml. [0102]
  • The use of a stabilizer in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: [0103] The Science and Practice of Pharmacy, 19th edition, 1995.
  • In a further embodiment of the invention the formulation further comprises a surfactant. In a further embodiment of the invention the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, such as 188 and 407, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g. Tween-20, or Tween-80), monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, glycerol, cholic acid or derivatives thereof, lecithins, alcohols and phospholipids, glycerophospholipids (lecithins, kephalins, phosphatidyl serine), glyceroglycolipids (galactopyransoide), sphingophospholipids (sphingomyelin), and sphingoglycolipids (ceramides, gangliosides), DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), dipalmitoyl phosphatidic acid, sodium caprylate, bile acids and salts thereof and glycine or taurine conjugates, ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate, N-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, anionic (alkyl-aryl-sulphonates) monovalent surfactants, palmitoyl lysophosphatidyl-L-serine, lysophospholipids (e.g. 1-acyl-sn-glycero-3-phosphate esters of ethanolamine, choline, serine or threonine), alkyl, alkoxyl (alkyl ester), alkoxy (alkyl ether)-derivatives of lysophosphatidyl and phosphatidylcholines, e.g. lauroyl and myristoyl derivatives of lysophosphatidylcholine, dipalmitoylphosphatidylcholine, and modifications of the polar head group, that is cholines, ethanolamines, phosphatidic acid, serines, threonines, glycerol, inositol, and the postively charged DODAC, DOTMA, DCP, BISHOP, lysophosphatidylserine and lysophosphatidylthreonine, zwitterionic surfactants (e.g. N-alkyl-N,N-dimethylammonio-1-propanesulfonates, 3-cholamido-1-propyldimethylammonio-1-propanesulfonate, dodecylphosphocholine, myristoyl lysophosphatidylcholine, hen egg lysolecithin), cationic surfactants (quarternary ammonium bases) (e.g. cetyl-trimethylammonium bromide, cetylpyridinium chloride), non-ionic surfactants, polyethyleneoxide/polypropyleneoxide block copolymers (Pluronics/Tetronics, Triton X-100, Dodecyl β-D-glucopyranoside) or polymeric surfactants (Tween-40, Tween-80, Brij-35), fusidic acid derivatives—(e.g. sodium tauro-dihydrofusidate etc.), long-chain fatty acids and salts thereof C6-C12 (eg. oleic acid and caprylic acid), acylcarnitines and derivatives, N[0104] α-acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, Nα-acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, Nα-acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
  • The use of a surfactant in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: [0105] The Science and Practice of Pharmacy, 19th edition, 1995.
  • In a further embodiment of the invention the GLP-1 compound is selected from GLP-1(7-36) or an analogue thereof having a lysine residue wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. In a further embodiment of the invention the GLP-1 compound is selected from a GLP-1(7-36) analogue having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. In a further embodiment of the invention the GLP-1 compound is selected from Arg26,34,Lys36GLP-1(7-36) having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. [0106]
  • In a further embodiment of the invention the GLP-1 compound is selected from GLP-1(7-37) or an analogue thereof having a lysine residue wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. In a further embodiment of the invention the GLP-1 compound is selected from a GLP-1(7-37) analogue having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. In a further embodiment of the invention the GLP-1 compound is selected from Arg34GLP-1(7-37), or Arg26GLP-1(7-37) having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. [0107]
  • In a further embodiment of the invention the GLP-1 compound is selected from GLP-1(7-38) or an analogue thereof having a lysine residue wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. In a further embodiment of the invention the GLP-1 compound is selected from a GLP-1(7-38) analogue having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. In a further embodiment of the invention the GLP-1 compound is selected from Gly8,Arg26,34,Glu37,Lys38GLP-1(7-38) having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine. [0108]
  • In a further embodiment of the invention the GLP-1 compound is selected from GLP-1(7-37) or an analogue thereof having one lipophilic substituent optionally attached via a spacer. In a further embodiment the lipophilic substituent is attached to any one of the amino acid residues in position 18-37, typically 26-34. In case of the GLP-1(7-36) analogue the lipophilic substituent is attached to any one of the amino acid residues in position 18-36, typically 26-34. In case of the GLP-1(7-38) analogue the lipophilic substituent is attached to any one of the amino acid residues in position 18-38, typically 26-34. [0109]
  • In the present text, the designation “an analogue” is used to designate a peptide wherein one or more amino acid residues of the parent peptide have been substituted by another amino acid residue and/or wherein one or more amino acid residues of the parent peptide have been deleted and/or wherein one or more amino acid residues have been added to the parent peptide. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent peptide or both. Typically “GLP-1(7-37) or an analogue thereof” comprises GLP-1(7-36), GLP-1(7-37), and GLP-1(7-38), and analogues thereof wherein at least one, preferably at least 3, more preferable at least 5 amino acid residues have been substituted by another amino acid residue. In the present context the GLP-1 compound binds to a GLP-1 receptor, preferably with an affinity constant (K[0110] D) or a potency (EC50) of below 1 μM, e.g. below 100 nM (measured as known in the art, see e.g. WO 98/08871). The term “GLP-1 compound” encompasses GLP-1(7-37) and analogues thereof as well as derivatives of any of the foregoing. Derivatives of GLP-1 analogues are GLP-1 analogues which are chemically modified by introducing e.g. ester, alkyl or lipophilic functionalities on one or more amino acid residues of GLP-1 analogues. Methods for identifying GLP-1 compounds are described in WO 93/19175 (Novo Nordisk A/S). Examples of suitable GLP-1 compounds which can be used in the present formulation have been disclosed in e.g WO 98/08871, WO 99/43705, WO 99/43706, WO 99/43707, WO 99/43708, WO 99/43341, which are incorporated herein by reference.
  • The term “lipophilic substituent” is characterised by comprising 4-40 carbon atoms and having a solubility in water at 20° C. in the range from about 0.1 mg/100 ml water to about 250 mg/100 ml water, such as in the range from about 0.3 mg/100 ml water to about 75 mg/100 ml water. For instance, octanoic acid (C8) has a solubility in water at 20° C. of 68 mg/100 ml, decanoic acid (C10) has a solubility in water at 20° C. of 15 mg/100 ml, and octadecanoic acid (C18) has a solubility in water at 20° C. of 0.3 mg/100 ml. [0111]
  • The lipophilic substituent may be attached to an amino group of the GLP-1(7-37) or an analogue thereof by means of a carboxyl group of the lipophilic substituent which forms an amide bond with an amino group of the amino acid residue to which it is attached. Alternatively, the lipophilic substituent may be attached to said amino acid residue in such a way that an amino group of the lipophilic substituent forms an amide bond with a carboxyl group of the amino acid residue. As a further option, the lipophilic substituent may be linked to the GLP-1(7-37) or an analogue thereof via an ester bond. Formally, the ester can be formed either by reaction between a carboxyl group of the GLP-1(7-37) or an analogue thereof and a hydroxyl group of the substituent-to-be or by reaction between a hydroxyl group of the GLP-1(7-37) or an analogue thereof and a carboxyl group of the substituent-to-be. As a further alternative, the lipophilic substituent can be an alkyl group which is introduced into a primary amino group of the GLP-1(7-37) or an analogue thereof. [0112]
  • In a further alternative, the lipophilic substituent may be attached to the GLP-1(7-37) or an analogue thereof by means of a spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the GLP-1(7-37) or an analogue thereof. A spacer must contain at least two functional groups, one to attach to a functional group of the lipophilic substituent and the other to a functional group of the parent GLP-1(7-37) or an analogue thereof. The term “spacer” is used in the present text to designate a bivalent moiety which contain at least two functional groups, one to attach to a functional group of the lipophilic substituent and the other to a functional group of the GLP-1 compound. Examples of suitable spacers are succinic acid, lysyl, glutamyl, asparagyl, glycyl, beta-alanyl and gamma-aminobutanoyl, or a dipeptide such as Gly-Lys, each of which constitutes an individual embodiment. When the spacer is succinic acid, one carboxyl group thereof may form an amide bond with an amino group of the amino acid residue, and the other carboxyl group thereof may form an amide bond with an amino group of the lipophilic substituent. When the spacer is lysyl, glutamyl, asparagyl, glycyl, beta-alanyl or gamma-aminobutanoyl, the carboxyl group thereof may form an amide bond with an amino group of the amino acid residue, and the amino group thereof may form an amide bond with a carboxyl group of the lipophilic substituent. When Lys is used as the spacer, a further spacer may in some instances be inserted between the ε-amino group of Lys and the lipophilic substituent. In one preferred embodiment, such a further spacer is succinic acid which forms an amide bond with the ε-amino group of Lys and with an amino group present in the lipophilic substituent. In another preferred embodiment such a further spacer is Glu or Asp which forms an amide bond with the ε-amino group of Lys and another amide bond with a carboxyl group present in the lipophilic substituent, that is, the lipophilic substituent is a N[0113] ε-acylated lysine residue. In an embodiment, the spacer is an amino acid residue except Cys or Met, or a dipeptide such as Gly-Lys. For purposes of the present invention, the phrase “a dipeptide such as Gly-Lys” means any combination of two amino acids except Cys or Met, typically a dipeptide wherein the C-terminal amino acid residue is Lys, His or Trp, typically Lys, and the N-terminal amino acid residue is Ala, Arg, Asp, Asn, Gly, Glu, Gln, lle, Leu, Val, Phe, Pro, Ser, Tyr, Thr, Lys, His and Trp. Typically, an amino group of the GLP-1 compound forms an amide bond with a carboxylic group of the amino acid residue or dipeptide spacer, and an amino group of the amino acid residue or dipeptide spacer forms an amide bond with a carboxyl group of the lipophilic substituent.
  • In a further embodiment of the invention the lipophilic substituent has from 8 to 40 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 10 to 24 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 12 to 24 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 12 to 18 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 14 to 18 carbon atoms. [0114]
  • In a further embodiment of the invention the spacer is present. In a further embodiment of the invention the spacer is selected from an amino acid. In a further embodiment of the invention, the spacer is an amino acid residue except Cys or Met. In another embodiment, the spacer is a dipeptide such as Gly-Lys. In a further embodiment the spacer is selected from lysyl, glutamyl, asparagyl, glycyl, beta-alanyl and gamma-aminobutanoyl, each of which constitutes an individual embodiment. Typically used spacers are glutamyl, aminobutyroyl, and beta-alanyl (beta-Ala). [0115]
  • In another embodiment, the spacer is an unbranched alkane α,ω-dicarboxylic acid group having from 1 to 7 methylene groups, which spacer forms a bridge between an amino group of the parent peptide and an amino group of the lipophilic substituent. Typically, the spacer is succinic acid. [0116]
  • The lipophilic substituent(s) contain a functional group which can be attached to one of the following functional groups of an amino acid of the parent GLP-1(7-37) or an analogue thereof: [0117]
  • (a) the amino group attached to the alpha-carbon of the N-terminal amino acid, [0118]
  • (b) the carboxy group attached to the alpha-carbon of the C-terminal amino acid, [0119]
  • (c) the epsilon-amino group of any Lys residue, [0120]
  • (d) the carboxy group of the R group of any Asp and Glu residue, [0121]
  • (e) the hydroxy group of the R group of any Tyr, Ser and Thr residue, [0122]
  • (f) the amino group of the R group of any Trp, Asn, Gln, Arg, and His residue, or [0123]
  • (g) the thiol group of the R group of any Cys residue. [0124]
  • In a further embodiment of the invention, the lipophilic substituent is attached to the carboxy group of the R group of any Asp and Glu residue. [0125]
  • In a further embodiment of the invention, a lipophilic substituent is attached to the carboxy group attached to the alpha-carbon of the C-terminal amino acid. [0126]
  • In a further embodiment of the invention, a lipophilic substituent is attached to the epsilon-amino group of any Lys residue. [0127]
  • Each lipophilic substituent contains a functional group which may be attached to a functional group of an amino acid of the parent GLP-1(7-37) or an analogue thereof. For example, a lipophilic substituent may contain a carboxyl group which can be attached to an amino group of the parent GLP-1(7-37) or an analogue thereof by means of an amide bond. [0128]
  • In a further embodiment of the invention, the lipophilic substituent comprises a partially or completely hydrogenated cyclopentanophenathrene skeleton. [0129]
  • In a further embodiment of the invention, the lipophilic substituent is a straight chain or branched alkyl group. [0130]
  • In a further embodiment of the invention, the lipophilic substituent is an acyl group of a straight-chain or branched fatty acid. [0131]
  • In a further embodiment of the invention the lipophilic substituent is an acyl group having the formula CH[0132] 3(CH2)nCO—, wherein n is an integer from 4 to 38. In a further embodiment n is an integer from 12 to 38. In further embodiments the lipophilic substituent is selected from the following individual embodiments CH3(CH2)12CO—, CH3(CH2)14CO—, CH3(CH2)16CO—, CH3(CH2)18CO—, CH3(CH2)20CO— and CH3(CH2)22CO—. In a specific embodiment, the lipophilic substituent is tetradecanoyl. In another specific embodiment, the lipophilic substituent is hexadecanoyl.
  • In another embodiment of the present invention, the lipophilic substituent has a group which is negatively charged such as a carboxylic acid group. For example, the lipophilic substituent may be an acyl group of a straight-chain or branched alkane α,ω-dicarboxylic acid of the formula HOOC(CH[0133] 2)mCO—, wherein m is an integer from 4 to 38, preferably an integer from 12 to 38, and most preferably is HOOC(CH2)14CO—, HOOC(CH2)16CO—, HOOC(CH2)18CO—, HOOC(CH2)20CO— or HOOC(CH2)22CO—.
  • In a further embodiment of the invention the GLP-1 compound is Arg[0134] 26,34,Lys36-(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-36).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0135] 26,Lys34-(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-37).
  • In a further embodiment of the invention the GLP-1 compound is Gly[0136] 8,Arg26,34, Glu37, Lys38-(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-38).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0137] 34,Lys26-(N-epsilon-(gamma-aminobutyroyl(N-gamma-hexadecanoyl)))-GLP-1(7-37).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0138] 34,Lys26-(N-epsilon-(beta-alanyl(N-beta-hexadecanoyl)))-GLP-1(7-37).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0139] 34,Lys26-(N-epsilon-(beta-alanyl-(N-beta-tetradecanoyl)))-GLP-1(7-37).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0140] 34,Lys26-(N-epsilon-(gamma-aminobutyroyl)-(N-gamma-tetradecanoyl))-GLP-1-(7-37).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0141] 34,Lys26-(N-epsilon-(beta-alanyl-(N-beta-16-hydroxyhexadecanoyl)))-GLP-1(7-37).
  • In a further embodiment of the invention the GLP-1 compound is Arg[0142] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0143] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0144] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0145] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0146] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0147] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0148] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0149] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0150] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0151] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0152] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0153] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0154] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0155] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0156] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0157] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0158] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0159] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0160] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0161] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0162] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0163] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0164] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0165] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0166] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0167] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0168] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0169] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0170] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0171] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0172] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1 (7-37), glycylglycine, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0173] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0174] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0175] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0176] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0177] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0178] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0179] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0180] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0181] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0182] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0183] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0184] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0185] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0186] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0187] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0188] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0189] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0190] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0191] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0192] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 1 mg/ml EDTA or 1.55 mg/ml L-His, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0193] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1 mg/ml EDTA/1.55 mg/ml L-His, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0194] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0195] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0196] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0197] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 7 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0198] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 7 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0199] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 7 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0200] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 1 mg/ml EDTA or 1.55 mg/ml L-His, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0201] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 1 mg/ml EDTA or 1 .55 mg/ml L-His, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0202] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0203] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0204] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0205] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0206] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0207] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0208] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0209] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0210] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0211] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0212] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0213] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1 (7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0214] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0215] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg[0216] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg[0217] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg[0218] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg[0219] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • Typically the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg[0220] 34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • Any possible combination of two or more of the embodiments described herein is comprised within the scope of the present invention. [0221]
  • The parent peptide, GLP-1(7-37) or analogue thereof, can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture. [0222]
  • The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question. [0223]
  • The DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the peptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, [0224] Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989). The DNA sequence encoding the peptide may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Leffers 22 (1981), 1859-1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801-805. The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in U.S. Pat. No. 4,683,202 or Saiki et al., Science 239 (1988), 487-491.
  • The DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. [0225]
  • The vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra. [0226]
  • The DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences. The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. [0227]
  • The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate. [0228]
  • To direct a parent peptide of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame. Secretory signal sequences are commonly positioned 5′ to the DNA sequence encoding the peptide. The secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein. [0229]
  • The procedures used to ligate the DNA sequences coding for the present peptide, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., supra). [0230]
  • The host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells. Examples of suitable host cells well known and used in the art are, without limitation, [0231] E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.
  • EXAMPLES OF PHARMACEUTICAL FORMULATIONS
  • In the following “Compound 1” is intended to mean: Arg[0232] 34, Lys26(Nε-(γ-Glu(Nα-hexadecanoyl))) GLP-1(7-37).
  • Physical stability of the formulations is evaluated by means of visual inspection and turbidity after storage of the formulation in top filled glass cartridges for various time periods. The cartridges are stored at 50° C.±3° C. and/or at elevated temperatures (e.g. 25° C. or 37° C.). [0233]
  • Visual inspection of the formulations is performed in a sharp focused light with a dark background. The turbidity of the formulation is characterized by a visual score ranking the degree of turbidity from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3). A formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight. [0234]
  • The turbidity is also measured in Nephelometric Turbidity Units (NTU) with a nephelometer, which has been calibrated with a Formazin standard. A formulation with a turbidity>>10 NTU is regarded as physical unstable. [0235]
  • Infrared measurements have shown that the turbididy is protein related. Hence, precipitate in a turbid Compound 1 sample has been isolated after centrifugation as a semisolid pellet. Fourier Transform Infrared measurements in the amide region on the pellet shows high absorption and increased amounts of β-sheet structure and a concomitant decrease in α-helix relative to compound 1 in solution, which is consistent with aggregated compound 1. [0236]
  • Example 1
  • Preservative, isotonic agent and buffer were dissolved and pH was adjusted to the specified pH. Hereafter the Compound 1 or GLP1(7-37) was dissolved under slow stirring. The pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid. Finally, the formulation was sterilised by filtration through a 0.22 μm sterile filter. [0237]
    Visual
    inspection at Turbidity
    Isotonic 5° C. (visual measurements
    Compound Amount pH Buffer agent Preservative score) at 5° C. (NTU)
    Arg34, 3 mg/ml 7.9 Disodium Mannitol Phenol 1.5 0.9
    Lys26(Nε-(γ-Glu(Nα- hydrogen 36.9 mg/ml 5 mg/ml (12 weeks) (6 weeks)
    hexadecanoyl))) phosphate
    GLP-1 (7-37).
    GLP1(7-37) 3 mg/ml 7.9 Disodium Mannitol Phenol 3   364
    hydrogen 36.9 mg/ml 5 mg/ml (1 day) (1 day)
    phosphate
  • It is seen that a formulation with GLP1(7-37) is physically unstable after just 1 day as it has a visual score corresponding to 3 and a turbidity of 364 NTU, whereas a formulation with Compound 1 is physically stable for more than 12 weeks. [0238]
  • Example 2
  • Buffer was dissolved and pH was adjusted to the specified pH. Hereafter the Compound 1 was dissolved under slow stirring. The pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid. Finally, the formulation was sterilised by filtration through a 0.22 μm sterile filter. [0239]
  • The physical stability is evaluated by visual inspection and Turbidity measurements in NTU as described in Example 1. [0240]
    Visual inspection Turbidity
    Amount of at 5° C. measurements at
    compound 1 PH Buffer (visual score) 5° C. (NTU)
    80 mg/ml 7.4 Disodium 1 4.7
    hydrogen (8 months)  (10 months)
    phosphate
    80 mg/ml 7.4 Disodium 1 4.9
    hydrogen (22 months) (22 months)
    phosphate
  • It is seen that the formulation is physically stable for more than 22 months. [0241]
  • Example 3
  • Preservative and buffer was dissolved and pH was adjusted to the specified pH. Hereafter the Compound 1 was dissolved under slow stirring. The pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid. Finally, the formulation was sterilised by filtration through a 0.22 μm sterile filter. [0242]
  • The physical stability is evaluated by visual inspection and Turbidity measurements in NTU as described in Example 1. [0243]
    Visual
    Amount of inspection at Turbidity
    compound 5° C. (visual measurements
    1 PH Buffer Preservative score) at 5° C. (NTU)
    80 mg/ml 7.4 Disodium Phenol 1 4.3
    hydrogen 10 mg/ml (8 months)  (10 months)
    phosphate
    80 mg/ml 7.4 Disodium Phenol 1 5.3
    hydrogen 10 mg/ml (22 months) (22 months)
    phosphate
  • It is seen that the formulation is physically stable for more than 10 months and even for more than 22 months. [0244]
  • Example 4
  • Preservative, isotonic agent and buffer were dissolved and pH was adjusted to the specified pH. Hereafter the Compound 1 was dissolved under slow stirring. The pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid. Finally, the formulation was sterilised by filtration through a 0.22 μm sterile filter. [0245]
  • The physical stability is evaluated by visual inspection and Turbidity measurements in NTU as described in Example 1. [0246]
    Visual
    inspection at Turbidity
    Amount of Isotonic 5° C. (visual measurements
    Compound 1 PH Buffer agent Preservative score) at 5° C. (NTU)
    0.3 mg/ml   7.4 Sodium dihydrogen Mannitol Phenol 0   0.6
    phosphate/ 36.9 mg/ml  5 mg/ml (24 months) (24 months)
    disodium hydrogen
    phosphate
    3 mg/ml 7.9 glycylglycine Glycerol Phenol 0.5 2.1
    16.0 mg/ml  5 mg/ml (12 weeks) (6 weeks)
    3 mg/ml 7.9 glycylglycine Glycerol Phenol 1   0.7
    16.0 mg/ml  5 mg/ml (15 months) (15 months)
    1 mg/ml 7.0 Sodium dihydrogen Mannitol Benzylalcohol 0.5 1.7
    phosphate/ 17.0 mg/ml 18 mg/ml (9 months)  (11 months)
    disodium hydrogen
    phosphate
    1 mg/ml 7.0 Sodium dihydrogen Mannitol Benzylalcohol 0.5 1.7
    phosphate/ 17.0 mg/ml 18 mg/ml (22 months) (22 months)
    disodium hydrogen
    phosphate
    1 mg/ml 7.0 Sodium dihydrogen Mannitol m-cresol 0   1.5
    phosphate/ 38.5 mg/ml (3 mg/ml) and (9 months)  (11 months)
    disodium hydrogen phenol
    phosphate (1.5 mg/ml)
    1 mg/ml 7.0 Sodium dihydrogen Mannitol m-cresol 0.5 1.9
    phosphate/ 38.5 mg/ml (3 mg/ml) and (22 months) (22 months)
    disodium hydrogen phenol
    phosphate (1.5 mg/ml)
    5 mg/ml 7.8 Sodium dihydrogen Mannitol Benzylalcohol 0.5 1.8
    phosphate/ 17.0 mg/ml 18 mg/ml (9 months)  (11 months)
    disodium hydrogen
    phosphate
    5 mg/ml 7.8 Sodium dihydrogen Mannitol Benzylalcohol 1   1.5
    phosphate/ 17.0 mg/ml 18 mg/ml (22 months) (22 months)
    disodium hydrogen
    phosphate
    3 mg/ml 9.4 glycine Mannitol Phenol 0.5 0.7
    36.9 mg/ml  5 mg/ml (2½ months) (2 months) 
    3 mg/ml 9.4 glycine Mannitol Phenol 1   0.7
    36.9 mg/ml  5 mg/ml (14 months) (14 months)
  • It is seen that some of the formulations has already been measured to be stable for more than 14 months and some more than 22 months. [0247]
  • Example 5
  • Preservative, isotonic agent, buffer, and further additive(s) selected from chelating agent, stabiliser and surfactant were dissolved and pH was adjusted to the specified pH. Hereafter the Compound 1 was dissolved under slow stirring. The pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid. Finally, the formulation was sterilised by filtration through a 0.22 μm sterile filter. [0248]
  • The physical stability is evaluated by visual inspection and Turbidity measurements in NTU as described in Example 1. [0249]
    Visual
    Chelating inspection at Turbidity
    Amount of Isotonic agent/stabiliser/ 5° C. (visual measurements
    compound 1 PH Buffer agent Preservative surfactant score) at 5° C. (NTU)
    3 mg/ml 9.4 Glycine Mannitol Phenol EDTA 0.5 1.2
    36.9 mg/ml 5 mg/ml (1 mg/ml)/ (2½ months) (2 months) 
    L-Histidin
    (1.55 mg/ml)
    3 mg/ml 9.4 Glycine Mannitol Phenol EDTA 0.5 0.9
    36.9 mg/ml 5 mg/ml (1 mg/ml)/ (14 months) (14 months)
    L-Histidin
    (1.55 mg/ml)
    3 mg/ml 9.4 glycine Mannitol Phenol Poloxamer 188 1   1.3
    36.9 mg/ml 5 mg/ml (4 mg/ml)/ (2½ months) (2 months) 
    PEG 35000
    (30 mg/ml)  
    3 mg/ml 9.4 glycine Mannitol Phenol Poloxamer 188 1   0.8
    36.9 mg/ml 5 mg/ml (4 mg/ml)/ (14 months) (14 months)
    PEG 35000
    (30 mg/ml)  
    80 mg/ml  7.4 Disodium none none LPCM 0   7.3
    hydrogen 19 mg/ml (8 months)  (10 months)
    phosphate
    80 mg/ml  7.4 Disodium none none LPCM 1   8.1
    hydrogen 19 mg/ml (22 months) (22 months)
    phosphate
  • It is seen that some of the formulations has already been measured to be stable for more than 14 months and some more than 22 months. [0250]
  • Example 6
  • Preservative, isotonic agent and buffer were dissolved and pH adjusted to the specified pH. Hereafter the Compound was dissolved under slow stirring. The pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid. Finally, the formulation was sterilised by filtration through a 0.22 μm sterile filter. The physical stability was followed at 5, 25 and 37° C. [0251]
  • The physical stability is evaluated by visual inspection and Turbidity measurements in NTU as described in Example 1. [0252]
    Visual Turbidity
    Amount of Isotonic inspection measurements
    Compound 1 PH Buffer agent Preservative Temp. (visual score) (NTU)
    3 mg/ml 8.4 Disodium Glycerol Phenol  5° C. 0.5 1.0
    hydrogen 16.0 mg/ml 7 mg/ml (12 weeks) (6 weeks)
    phosphate
    3 mg/ml 8.4 Disodium Glycerol Phenol  5° C. 1   0.6
    hydrogen 16.0 mg/ml 7 mg/ml (15 months) (15 months)
    phosphate
    3 mg/ml 8.4 Disodium Glycerol Phenol 25° C. 0.5  1.00
    hydrogen 16.0 mg/m 7 mg/ml (12 weeks) (8 weeks)
    phosphate
    3 mg/ml 8.4 Disodium Glycerol Phenol 37° C. 1   1.1
    hydrogen 16.0 mg/m 7 mg/ml (12 weeks) (8 weeks)
    phosphate
  • It is seen that the formulation is physically stable after storage at 5° C. for more than 15 months and after storage at, 25 and 37° C. it is physically stable for more than 12 weeks. [0253]
  • Example 7
  • The chemical stability of modified GLP-1 can be significantly improved by the use of certain amino acids (charged-basic) and imidazole as stabilizers. [0254]
    Dimer
    Purity, formation,
    Compound 1 Compound 1
    (%) T = (%) T =
    Composition pH Temperature 12 weeks 12 weeks
      3 mg/ml Compound 1 7.4 37° C. 78.4 5.43
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
      5 mg/ml phenol
    36.9 mg/ml mannitol
      3 mg/ml Compound 1 7.4 37° C. 85.9 3.28
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
      5 mg/ml phenol
    36.9 mg/ml mannitol
    1.55 mg/ml L-histidine
      3 mg/ml Compound 1 7.4 37° C. 86.2 1.88
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
      5 mg/ml phenol
    36.9 mg/ml mannitol
    7.75 mg/ml L-histidine
      3 mg/ml Compound 1 7.4 37° C. 85.3 3.70
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
      5 mg/ml phenol
    36.9 mg/ml mannitol
    1.74 mg/ml L-arginine
      3 mg/ml Compound 1 7.4 37° C. 74.3 3.42
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
      5 mg/ml phenol
    36.9 mg/ml mannitol
    0.68 mg/ml imidazole
      2 mg/ml Compound 1 7.7 37° C. 88.5 7.74
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
     5.5 mg/ml phenol
      16 mg/ml glycerol
      2 mg/ml Compound 1 8.0 37° C. 88.2 7.62
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
     5.5 mg/ml phenol
      16 mg/ml glycerol
      2 mg/ml Compound 1 7.7 37° C. 90.4 4.71
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
     5.5 mg/ml phenol
      16 mg/ml glycerol
    1.55 mg/ml histidine
      2 mg/ml Compound 1 8.0 37° C. 90.6 4.67
    1.42 mg/ml disodium
    hydrogenphosphate,
    dihydrate
     5.5 mg/ml phenol
      16 mg/ml glycerol
    1.55 mg/ml histidine
  • From the above table it appears that the purity of Compound 1, analyzed by RP-HPLC, is significantly improved in preparations comprising histidine or arginine as stabilizers. Furthermore the formation of Compound 1 dimers, analyzed by SE-HPLC, is clearly reduced in preparations with imidazole, histidine and arginine. [0255]

Claims (25)

1. A pharmaceutical formulation comprising a GLP-1 compound and a buffer, wherein:
(i) said GLP-1 compound is (a) GLP-1(7-37) or (b) an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer;
(ii) said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml; and
(iii) aid formulation has a pH from 7.0 to 10;
provided that if an isotonic agent is present and the pH of the formulation is 7.4, then mannitol or NaCl is not the isotonic agent.
2. The formulation according to claim 1, wherein the concentration of said GLP-1 compound is from 1 mg/ml to 100 mg/ml.
3. The formulation according to claim 1, further comprising water.
4. The formulation according to claim 1, wherein said pH is from 7.5 to 10.
5. The formulation according to claim 1, wherein the concentration of said GLP-1 compound is from 0.1 mg/ml to 10 mg/ml.
6. The formulation according to claim 2, wherein the concentration of said GLP-1 compound is 1-5mg/ml.
7. The formulation according to claim 1, further comprising a preservative.
8. The formulation according to claim 7, wherein said preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml.
9. The formulation according to claim 1, further comprising an isotonic agent.
10. The formulation according to claim 9, wherein said isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml.
11. The formulation according to claim 1, further comprising a chelating agent.
12. The formulation according to claim 11, wherein said chelating agent is present in a concentration from 0.1 mg/ml to 5 mg/ml.
13. The formulation according to claim 1, further comprising a stabiliser.
14. The formulation according to claim 13, wherein said stabiliser is selected from the group consisting of L-histidine, imidazole and arginine.
15. The formulation according to claim 13, wherein said stabiliser is a high molecular weight polymer and/or a low molecular weight compound and is present in a concentration from 0.1 mg/ml to 50 mg/ml.
16. The formulation according to claim 1, further comprising a surfactant.
17. The formulation according to claim 1, wherein said GLP-1 compound is selected from the group consisting of: GLP-1(7-36), GLP-1(7-37), and a GLP-1(7-38) analogue having a lysine residue and optionally a lipophilic substituent attached with or without a spacer to the epsilon amino group of said lysine.
18. The formulation according to claim 17, wherein said GLP-1(7-36), GLP-1(7-37), or GLP-1(7-38) analogue is selected from the group consisting of: Arg34GLP-1(7-37); Arg26,34,Lys36GLP-1(7-36); Arg26GLP-1(7-37); and Gly8,Arg26,34,Glu37,Lys38GLP-1(7-38).
19. The formulation according to claim 17, wherein said lipophilic substituent has from 8 to 40 carbon atoms.
20. The formulation according to claim 17, wherein said spacer is an amino acid.
21. The formulation according to claims 1, wherein said GLP-1 compound is Arg34, Lys26(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).
22. A method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, said method comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
23. The method according to claim 22, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml.
24. A method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, said method comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
25. The method according to claim 24, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml.
US10/185,923 2001-06-28 2002-06-27 Stable formulation of modified GLP-1 Abandoned US20030119734A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DKPA200101011 2001-06-28
DKPA200101010 2001-06-28
DKPA200101010 2001-06-28
DKPA200101011 2001-06-28
DKPA200101053 2001-07-04
DKPA200101052 2001-07-04
DKPA200101052 2001-07-04
DKPA200101053 2001-07-04
US30832501P true 2001-07-27 2001-07-27
US30829701P true 2001-07-27 2001-07-27
DKPA200200093 2002-01-18
DKPA200200092 2002-01-18
DKPA200200093 2002-01-18
DKPA200200092 2002-01-18
US10/185,923 US20030119734A1 (en) 2001-06-28 2002-06-27 Stable formulation of modified GLP-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/185,923 US20030119734A1 (en) 2001-06-28 2002-06-27 Stable formulation of modified GLP-1
US11/786,095 US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1
US12/785,861 US8846618B2 (en) 2001-06-28 2010-05-24 Stable formulation of modified GLP-1

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/786,095 Continuation US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 Continuation US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1

Publications (1)

Publication Number Publication Date
US20030119734A1 true US20030119734A1 (en) 2003-06-26

Family

ID=27545250

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/185,923 Abandoned US20030119734A1 (en) 2001-06-28 2002-06-27 Stable formulation of modified GLP-1
US11/786,095 Abandoned US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 Abandoned US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1
US12/785,861 Active US8846618B2 (en) 2001-06-28 2010-05-24 Stable formulation of modified GLP-1

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/786,095 Abandoned US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 Abandoned US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1
US12/785,861 Active US8846618B2 (en) 2001-06-28 2010-05-24 Stable formulation of modified GLP-1

Country Status (10)

Country Link
US (4) US20030119734A1 (en)
EP (1) EP1412384B1 (en)
JP (2) JP5562510B2 (en)
AT (1) AT382057T (en)
AU (1) AU2002316811A1 (en)
DE (1) DE60224284T2 (en)
DK (1) DK1412384T3 (en)
ES (1) ES2298378T3 (en)
PT (1) PT1412384E (en)
WO (1) WO2003002136A2 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20040209816A1 (en) * 1999-01-29 2004-10-21 Indu Parikh Treatment for diabetes
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060211616A1 (en) * 2003-08-21 2006-09-21 Novo Nordisk A/S Purification of glucagon-like peptides
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
US20060239924A1 (en) * 2002-02-27 2006-10-26 Bolotin Elijah M Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US20070010424A1 (en) * 2003-11-20 2007-01-11 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US20080171848A1 (en) * 2004-08-31 2008-07-17 Novo Nordisk A/S Use of Tris(Hydroxymethyl) Aminomethane For the Stabilization of Peptides, Polypeptides and Proteins
US20080234200A1 (en) * 2003-12-26 2008-09-25 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20080318865A1 (en) * 2003-06-03 2008-12-25 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US20090053169A1 (en) * 2007-08-20 2009-02-26 Pharmain Corporation Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same
US20090088387A1 (en) * 2007-08-03 2009-04-02 Pharmain Corporation Composition for long-acting peptide analogs
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20100056451A1 (en) * 2003-06-03 2010-03-04 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US20100173844A1 (en) * 2004-11-12 2010-07-08 Novo Nordisk A/S Stable Formulations of Peptides
US20100234299A1 (en) * 2001-06-28 2010-09-16 Novo Nordisk A/S Stable formulation of modified glp-1
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9737615B2 (en) 2005-12-19 2017-08-22 PharmalN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
JP5000848B2 (en) 2002-05-21 2012-08-15 賢治 寒川 Ghrelin-containing pharmaceutical compositions
BRPI0408978B1 (en) 2003-04-08 2018-05-15 Novo Nordisk A/S Process for regenerating a chromatographic stationary phase
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
CN1822851B (en) 2003-05-15 2011-04-13 塔夫茨大学信托人 Stable analogs of peptide and polypeptide therapeutics
CA2527743A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
BRPI0413276A (en) 2003-08-05 2006-10-10 Novo Nordisk As insulin derivative, zinc complex thereof, pharmaceutical composition and method for treating diabetes in a patient
JP5518282B2 (en) * 2003-09-01 2014-06-11 ノヴォ ノルディスク アー/エス Formulation of a stable peptide
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
MXPA06002941A (en) * 2003-09-19 2006-05-31 Novo Nordisk As Albumin-binding derivatives of therapeutic peptides.
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
TWI353250B (en) * 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
AT462409T (en) 2005-01-14 2010-04-15 Camurus Ab Topical bioadhesive formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
US8546326B2 (en) 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
CN1950078A (en) 2004-06-11 2007-04-18 诺和诺德公司 Counteracting drug-induced obesity using glp-1 agonists
CN101022822B (en) * 2004-08-24 2012-06-27 寒川贤治 Liquid preparation of physiologically active peptide
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) * 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
AU2005325510B2 (en) 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
AU2006224537A1 (en) * 2006-03-20 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
ES2397289T3 (en) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Fusion polypeptides of GLP-1 (glucagon like peptide 1) with increased resistance to peptidase
DE602006009631D1 (en) * 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 peptides containing spherical microcapsules, the production and use thereof
JP5552046B2 (en) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス Pharmaceutical formulation comprising insulin derivative
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
CN102046207B (en) 2008-03-31 2013-08-28 葛兰素集团有限公司 Drug fusions and conjugates
CN102112157B (en) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 Conjugated proteins with prolonged in vivo efficacy
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
CN102202683A (en) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 Treating diabetes melitus using insulin injections with less than daily injection frequency
KR101740066B1 (en) 2008-12-05 2017-05-25 글락소 그룹 리미티드 Methods for selecting protease resistant polypeptides
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
UY32514A (en) 2009-03-27 2010-10-29 Glaxo Group Ltd MERGERS & Conjugates of a drug insulinotropic AND SERUM HALF-LIFE WITH IMPROVED dAb
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг The stabilized growth hormone compound
BR112012018116A2 (en) 2010-01-22 2018-05-08 Novo Nordisk Healthcare Ag "Growth hormones with prolonged in vivo efficacy"
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2013083826A2 (en) 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
JP6059802B2 (en) 2012-07-01 2017-01-11 ノヴォ ノルディスク アー/エス The use of long-acting glp-1 peptide
CN103893744B (en) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 A pharmaceutical formulation for treating diabetes and a preparation method
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
CN103405753B (en) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 Exendin stable aqueous pharmaceutical composition needle
WO2015169789A1 (en) * 2014-05-07 2015-11-12 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
CN104800572A (en) * 2015-04-20 2015-07-29 陈兴田 Traditional Chinese medicine preparation for treating FD (Functional Dyspepsia) with depression and anxiety state
EP3295952A4 (en) * 2015-05-13 2018-12-12 Hangzhou Jiuyuan Gene Engineering Co., Ltd. Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
WO2018057977A1 (en) 2016-09-23 2018-03-29 Delpor, Inc. Stable compositions for incretin mimetic compounds
WO2019060735A1 (en) * 2017-09-21 2019-03-28 EMULATE, Inc. Physiology and pathophysiology of human gut: intestine-on-chip
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
EP0368864B1 (en) * 1987-05-14 1993-11-03 Commonwealth Scientific And Industrial Research Organisation Whey protein fractions
JPH03505401A (en) 1988-06-27 1991-11-28
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DE4002066A1 (en) 1990-01-25 1991-08-01 Basf Ag A process for removing riboflavin from fermentation suspensions
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (en) 1991-05-07 1991-05-07 Tomas Moks Peptide Hormone Solution
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK36492D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As Preparation
DK0642332T3 (en) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmic compositions containing cyclosporin
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
DE69422637D1 (en) 1993-11-19 2000-02-17 Searle & Co Transdermal composition (N- (N- (5- (4-aminoiminomethyl) phenyl-1-oxopentyl) -L-alpha-aspartyl) -L-phenylalanine or its esterderivaten and their salts pharmazeutischverwendbaren
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
AU1847695A (en) 1994-02-22 1995-09-04 Syntex-Synergen Neuroscience Joint Venture, The Pharmaceutical formulations of cntf
DK0699687T3 (en) 1994-08-31 2004-04-26 Mitsubishi Pharma Corp A process for purifying recombinant human serum albumin
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU4298596A (en) * 1994-12-23 1996-07-19 Novo Nordisk A/S Protracted glp-1 compositions
AT216590T (en) 1995-02-06 2002-05-15 Genetics Inst Drug formulations for il-12
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
DE69626976D1 (en) 1995-06-02 2003-04-30 Novozymes As TREATMENT OF A PROTEIN SOLUTION A1 / Fe AND ANSCHLIESENDE MEMBRANE CONCENTRATION
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
DE69722620T2 (en) 1996-07-03 2004-04-29 Alza Corp., Palo Alto Non-aqueous protic peptide preparations
JPH10101696A (en) 1996-08-08 1998-04-21 Japan Found Cancer Res Removal of contaminants included in protein expressed in transformant and purified protein therefrom
DE122009000079I2 (en) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle GLP-1 derivatives
EP0998942A4 (en) 1997-01-20 2006-08-16 Japan Energy Corp Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CO4750643A1 (en) 1997-06-13 1999-03-31 Lilly Co Eli Stable insulin formulation containing L-arginine and protamine
EP1036561A1 (en) 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Buccal, non-polar spray
DE69813599T2 (en) 1997-10-24 2004-04-08 Genentech, Inc., South San Francisco Cleaning of molecules
WO1999029336A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
DE29721752U1 (en) 1997-12-09 1998-02-12 Siemens Ag Crimp contact for connector systems
DE69942306D1 (en) * 1998-02-27 2010-06-10 Novo Nordisk As analog descendants of glp-1
JP2003522099A (en) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ Of glp-1 with delayed action profile glp-1 derivatives and exendin
WO1999043341A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6245572B1 (en) * 1998-05-01 2001-06-12 University Of Tennessee Research Corporation Flow cytometric characterization of amyloid fibrils
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
JP2002524514A (en) 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー Protein preparations
AT307603T (en) 1998-12-22 2005-11-15 Lilly Co Eli A storage stable liquid compositions of glucagon-like peptide-1
DE122007000001I1 (en) 1999-01-14 2007-06-28 Amylin Pharmaceuticals Inc New exendin agonist formulations and their administration
US6444788B1 (en) * 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
BR0009040A (en) * 1999-03-17 2001-12-18 Novo Nordisk As A method for acylating an amino group of a peptìdeoou of a protein, and the compound
WO2001000223A2 (en) 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
PL355378A1 (en) 1999-12-16 2004-04-19 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
CA2396920A1 (en) 2000-01-27 2001-08-02 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (glp-1) compounds
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
WO2002069994A2 (en) 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
AU4827701A (en) 2000-04-06 2001-10-23 Novo Nordisk As Shock heat treatment of polypeptides
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
JP4798833B2 (en) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 The method of producing human serum albumin comprising a heat treatment step
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
PT1360202E (en) * 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
WO2002098445A1 (en) 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Protein preparation
ES2298378T3 (en) * 2001-06-28 2008-05-16 Novo Nordisk A/S Stable formulation of GLP-1 modified.
CN1335182A (en) 2001-08-08 2002-02-13 华中科技大学 Insulin spray for oral cavity and its prepn process
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
US7462596B2 (en) 2002-03-15 2008-12-09 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
ES2308029T3 (en) 2002-09-25 2008-12-01 Novo Nordisk A/S Purification process comprising a microfiltration at high temperatures.
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
CA2527743A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
AT525083T (en) 2003-11-13 2011-10-15 Novo Nordisk As A pharmaceutical composition comprising an insulinotropic GLP-1 (7-37) analog Asp (B28) - insulin and a surface active compound
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
DK3300721T3 (en) * 2003-11-20 2019-05-27 Novo Nordisk As Propylenglycol-containing peptid formulations which are optimal for manufacture and for use in injection devices
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
EP1814581B1 (en) * 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
US8071103B2 (en) * 2006-07-18 2011-12-06 Centocor, Inc. Pharmaceutical composition comprising a human GLP-1 mimetibody
AR064623A1 (en) * 2006-12-21 2009-04-15 Centocor Inc Using receptor agonists glp -1 prolonged action to improve insulin sensitivity and lipid profiles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20040209816A1 (en) * 1999-01-29 2004-10-21 Indu Parikh Treatment for diabetes
US20090041731A1 (en) * 1999-01-29 2009-02-12 Indu Parikh Treatment for Diabetes
US8846618B2 (en) 2001-06-28 2014-09-30 Novo Nordisk A/S Stable formulation of modified GLP-1
US20100234299A1 (en) * 2001-06-28 2010-09-16 Novo Nordisk A/S Stable formulation of modified glp-1
US8277776B2 (en) 2002-02-27 2012-10-02 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20060093660A1 (en) * 2002-02-27 2006-05-04 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US8231859B2 (en) 2002-02-27 2012-07-31 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20060239924A1 (en) * 2002-02-27 2006-10-26 Bolotin Elijah M Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7790140B2 (en) 2002-02-27 2010-09-07 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20100221184A1 (en) * 2002-02-27 2010-09-02 Bolotin Elijah M Compositions for Delivery of Therapeutics and Other Materials
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US20100158806A1 (en) * 2002-02-27 2010-06-24 Bolotin Elijah M Compositions for Delivery of Therapeutics and Other Materials
US8257682B2 (en) 2002-02-27 2012-09-04 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7589169B2 (en) 2002-02-27 2009-09-15 Pharmain Corporation Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20100056451A1 (en) * 2003-06-03 2010-03-04 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US8114959B2 (en) 2003-06-03 2012-02-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20080318865A1 (en) * 2003-06-03 2008-12-25 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US8614181B2 (en) 2003-06-03 2013-12-24 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20100184687A1 (en) * 2003-08-21 2010-07-22 Novo Nordisk A/S Purification of Glucagon-Like Peptides
US20060211616A1 (en) * 2003-08-21 2006-09-21 Novo Nordisk A/S Purification of glucagon-like peptides
US20100190715A1 (en) * 2003-09-01 2010-07-29 Novo Nordisk A/S Stable Formulations of Peptides
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US8114833B2 (en) 2003-11-20 2012-02-14 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20070010424A1 (en) * 2003-11-20 2007-01-11 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20080234200A1 (en) * 2003-12-26 2008-09-25 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US20080171848A1 (en) * 2004-08-31 2008-07-17 Novo Nordisk A/S Use of Tris(Hydroxymethyl) Aminomethane For the Stabilization of Peptides, Polypeptides and Proteins
US20100173844A1 (en) * 2004-11-12 2010-07-08 Novo Nordisk A/S Stable Formulations of Peptides
US8748376B2 (en) * 2004-11-12 2014-06-10 Novo Nordisk A/S Stable formulations of peptides
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US9737615B2 (en) 2005-12-19 2017-08-22 PharmalN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20090088387A1 (en) * 2007-08-03 2009-04-02 Pharmain Corporation Composition for long-acting peptide analogs
US8518876B2 (en) 2007-08-03 2013-08-27 PharmalN Corporation Composition for long-acting peptide analogs
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US9657078B2 (en) 2007-08-03 2017-05-23 Pharmain Corporation Composition for long-acting peptide analogs
US9090664B2 (en) 2007-08-03 2015-07-28 Pharmain Corporation Composition for long-acting peptide analogs
US20110207662A1 (en) * 2007-08-03 2011-08-25 Pharmain Corporation Composition for Long-Acting Peptide Analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090053169A1 (en) * 2007-08-20 2009-02-26 Pharmain Corporation Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same
US8999930B2 (en) 2008-01-09 2015-04-07 Pharmain Corporation Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9562111B2 (en) 2008-01-09 2017-02-07 Pharmain Corporation Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
US10253079B2 (en) 2012-12-21 2019-04-09 Sanofi Functionalized Exendin-4 derivatives
US9745360B2 (en) 2012-12-21 2017-08-29 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Also Published As

Publication number Publication date
AT382057T (en) 2008-01-15
US20090111752A1 (en) 2009-04-30
US20080167226A1 (en) 2008-07-10
EP1412384A2 (en) 2004-04-28
US20100234299A1 (en) 2010-09-16
JP5562510B2 (en) 2014-07-30
WO2003002136A2 (en) 2003-01-09
US8846618B2 (en) 2014-09-30
WO2003002136A3 (en) 2004-03-04
AU2002316811A1 (en) 2003-03-03
DK1412384T3 (en) 2008-04-28
DE60224284T2 (en) 2008-12-18
JP2012051894A (en) 2012-03-15
DE60224284D1 (en) 2008-02-07
JP2004535442A (en) 2004-11-25
PT1412384E (en) 2008-03-28
EP1412384B1 (en) 2007-12-26
ES2298378T3 (en) 2008-05-16

Similar Documents

Publication Publication Date Title
JP5351884B2 (en) Suspension formulation and use of insulinotropic peptide
US8343914B2 (en) Fibrillation resistant proteins
JP5890085B2 (en) Glucagon analogs showing a solubility improved in buffer at physiological pH
CN1882356B (en) Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US8557769B2 (en) Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
AU2006224536B9 (en) Acylated GLP-1 compounds
JP4689833B2 (en) Storage stable formulation of glucagon-like peptide-1
AU765584B2 (en) Protein formulations
US8486890B2 (en) Amylin derivatives
ES2332057T3 (en) Muteins of fibroblast growth factor 21.
ES2334864T5 (en) Peptide-2 and glucagon-therapeutic use
EP1478233B1 (en) Method for administering glp-1 molecules
ES2672770T3 (en) Derived peptide-1 glucagon and pharmaceutical use
EP1061946B1 (en) Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
US9920106B2 (en) GLP-1 compounds
US7781401B2 (en) Glucagon-like peptide-2 analogs
US8809499B2 (en) Fusion protein of human fibroblast growth factor-21 and exendin-4
US20110288003A1 (en) Amide based glucagon and superfamily peptide prodrugs
US9012398B2 (en) Acylated exendin-4 compounds
EP3412300A1 (en) Therapeutic agents comprising elastin-like peptides
EP1056775B1 (en) Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1231219B1 (en) GLucagon-like peptide-2 analogs
EP1863521B1 (en) Extended glp-1 compounds
US8772232B2 (en) Protracted exendin-4 compounds
EP2190460B1 (en) Peptides derivatized with a-b-c-d- and their therapeutical use

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FLINK, JAMES M.;LARSEN, SILKE MOLLER;JENSEN, SIMON BJERREGAARD;AND OTHERS;REEL/FRAME:013395/0205;SIGNING DATES FROM 20020829 TO 20020918

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION